Skip to main content
Toggle navigation
Search
Home
Poster Schedule
Home
Poster Schedule
All Days
Wed, Sep 17
Thu, Sep 18
Fri, Sep 19
Poster Schedule
Type here to filter the list
Wednesday, September 17, 2025
(PA-084) Drivers of Primary Resistance to BCMA-targeted T Cell Redirected Therapies in High Tumor Burden
(PA-488) Efficacy and Safety of a China-developed BCMA-targeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-world Multicenter Experience
(PA-001) BCMA-Directed CAR-NK and BiKE Therapies Enhance NK Cell Cytotoxicity in Primary Multiple Myeloma
(PA-005) The Role of Trogocytosis in BCMA CAR T Cell Therapy with Gamma-Secretase Inhbition
(PA-006) Comparative Effectiveness of Teclistamab vs Real-world Physician’s Choice of Carfilzomib-and/or Pomalidomide-based Regimens in Locommotion and Momment in TCE RRMM
(PA-008) Economic Value of Tocilizumab Prophylaxis to Prevent Cytokine Release Syndrome (CRS) During Outpatient Teclistamab (Tec) or Talquetamab (Tal) Initiation for Relapsed/refractory Multiple Myeloma (RRMM)
(PA-011) Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
(PA-012) Clonal Hematopoiesis of Indeterminate Potential (CHIP) Does Not Impact the Efficacy of BCMA Directed Chimeric Antigen Receptor (CAR)-T Cells in Patients with Relapsed/refractory Multiple Myeloma
(PA-014) Outpatient Step-up Dosing of Teclistamab (TEC): An Implementation Process Shifting from the Academic Inpatient (IP) to Community Outpatient (OP) Setting
(PA-017) Bispecific Outpatient Step-up Dosing with Prophylactic Dexamethasone: The BOSS Program Experience in Myeloma
(PA-018) Severe Tumor Flare Pain Syndrome During Step-Up Dosing of Teclistamab in High-Risk Relapsed/Refractory Multiple Myeloma
(PA-020) Real-world Outcomes Among Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Initiating Teclistamab (Tec) at a Large Community Oncology Center in the US
(PA-024) Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series
(PA-025) Monitoring and Management of CMV and Other Viral Reactivations with Bispecific Antibodies (BsAbs) for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
(PA-026) Evaluation of Sequential Absolute Lymphocyte Count (ALC) in Patients with Relapsed Multiple Myeloma (RRMM) with Cranial Nerve Palsies (CNPs) Post Ciltacabtagene-autoleucel (cilta-cel)
(PA-028) Development of anti-AL amyloidosis CAR Phagocyte Therapy
(PA-031) Safety, Efficacy and Health After Teclistamab (SEHAT Study) in Patients with Relapsed and Refractory Multiple Myeloma; A Multicentric Real World Indian Experience
(PA-032) Immune Correlates of Response to T-Cell Engaging Bispecific Antibody Treatments in Multiple Myeloma
(PA-035) Clinical Outcomes After Teclistamab Failure in Relapsed/Refractory Multiple Myeloma
(PA-038) Optimizing the Use of Chimeric Antigen Receptor T-cell (CART) Therapy for Relapsed/refractory Myeloma
(PA-040) Overcoming Resistance in CD44-Overexpressing Myeloma through combination therapy with ATRA, Bortezomib, and NK Cells
(PA-045) Elranatamab Fixed Dosing: The Optimal Dosing Strategy for Safety, Efficacy, and Convenience Across Body Weights
(PA-046) Efficacy and Safety of Less Frequent Dosing With Elranatamab (ELRA) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): A US Subgroup Analysis from MagnetisMM-3
(PA-048) Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients
(PA-051) Initial Results of a Phase 2 Study to Evaluate Elranatamab (elran) Post-idecabtagene Vicleucel (ide-cel) Consolidation (EPIC) in Patients with Relapsed/refractory Multiple Myeloma (RRMM)
(PA-052) BCMA CAR-T Cells Capable of il-6-neutralization Bifunctionally Reduce Cytokine Release Syndrome and IL-6-driven Myeloma Growth in Preclinical Models
(PA-055) CAR-Tscm Cells as an Effective Immune Treatment to Multiple Myeloma Patients
(PA-059) A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
(PA-060) Phase 2 Study of Talquetamab (Tal) + Teclistamab (Tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Extramedullary Disease (EMD): RedirecTT-1
(PA-062) Serologic Immunity to Measles, Mumps, and Rubella in Multiple Myeloma Patients Following Cellular Therapy: A Descriptive Analysis
(PA-064) Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial
(PA-068) Impact of Neighborhood-level Disadvantage, Travel Distance, and Travel Time on Clinical Outcomes of Multiple Myeloma (MM) Patients Treated with Standard of Care (SOC) Idecabtagene Vicleucel (IDE-CEL)
(PA-069) Integrating Real-world Evidence to Augment Crossover Adjustment in KarMMa-3: A Case Study in Relapsed/Refractory Multiple Myeloma
(PA-071) Real-World Safety and Efficacy of BCMA Bispecific Antibodies in Relapsed and Refractory Light Chain Amyloidosis
(PA-074) Circulating Plasma Cells Evaluation Before and After CAR T-cell Therapy as a Dynamic Factor for Response Assessment
(PA-075) Macrophage Activation Syndrome-Like in Multiple Myeloma Patients Treated with the Academic Bcma-Directed Car-T Ari0002h: Genomic Insights and Clinical Implications
(PA-076) Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
(PA-078) Optimizing Post–Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Idecabtagene Vicleucel (ide-cel) Pivotal Clinical Trials and Real-World Experience
(PA-082) Real-world Outcomes of Patients with Multiple Myeloma Who Received BCMA-targeted Bispecific Antibodies in British-Columbia
(PA-087) Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Teclistamab
(PA-090) Deficiencies in Cellular Immunity Associated with Increased Risk of Infection with Bispecific Antibody Therapy in Multiple Myeloma
(PA-093) Outcomes of CAR-T Cell Therapy in patients with AL Amyloidosis
(PA-097) Prophylactic Dexamethasone (dex) with Outpatient Step-Up Dosing (SUD) of Bispecific Antibodies (BsAb) in Multiple Myeloma (MM) v. Standard of Care (SOC) Inpatient Observation
(PA-100) Efficacy of Subsequent T Cell Engagers Following BCMA CAR-T Therapy in Patients with Relapsed/refractory Multiple Myeloma: A Systematic Review and Meta-analysis
(PA-103) Value of the Treatment-free Period Following Ciltacabtagene Autoleucel Infusion in Patients with Relapsed/refractory Multiple Myeloma: Preliminary Findings from a Qualitative Interview Study
(PA-107) Impact of Frailty Tools on Outcomes in Myeloma: MRP and Simplified Index Predict Survival but Differ in Infection Risk Stratification
(PA-110) Denosumab-Related Osteonecrosis of the Jaw in Patients with Multiple Myeloma: A Chinese Single-Center Retrospective Cohort Study
(PA-116) Progression Patterns by Positron Emission Tomography (PET) for Relapsed / Refractory Multiple Myeloma (RRMM) After CAR T Cell Therapy: Potential Role for Radiotherapy (RT)?
(PA-119) When ICAN(S) Becomes ICAN’T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading
(PA-122) Inadequate Racial Reporting Among References Forming the Basis of NCCN Guidelines for Multiple Myeloma and Systemic Light Chain Amyloidosis
(PA-125) Physical Activity Patterns, Barriers, and Motivators in Multiple Myeloma and Precursor Disease Patients: A Cross-Sectional Survey
(PA-128) Measles Antibody IgG Levels in Treatment Exposed Patients with Multiple Myeloma
(PA-132) Current Survival and Causes of Mortality of Myeloma Patients in Real Word Setting
(PA-139) Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid
(PA-142) Assessment of Extraosseous Multiple Myeloma Using Whole-Body Imaging Techniques: PET/CT, MRI, and MIBI
(PA-145) Treatment-Free Hospitalization-Free Time With CAR T-Cell Therapy Versus Standard Regimens and Quality of Life Implications in Patients With Relapsed/Refractory MM: Findings From the KarMMa-3 Trial
(PA-147) Nutritional Status of Adults with Multiple Myeloma and Its Association with Disease Progression and Survival
(PA-150) Obesity as a Prognostic Factor in Newly Diagnosed Multiple Myeloma in a Mexican Population
(PA-153) Operationalising Patient Selection for Outpatient Transplant in Multiple Myeloma: Subjective versus Objective Measures
(PA-156) "Challenges in Diagnosis, Treatment Access, and Quality of Life Among Newly Diagnosed Multiple Myeloma Patients in India: Findings from a Prospective Observational Study"
(PA-159) Performance of Deauville Score and Total Lesion Glycolysis as Response Markers for Multiple Myeloma with Extramedullary Disease
(PA-165) Testing and Validating a Mass Spectrometry Based Algorithm for Response Assessment in Myeloma
(PA-169) Mass Spectrometry vs. 10-5 MRD Detection by Next-Generation Flow and Sequencing in Multiple Myeloma: Results from the Cassiopeia Clinical Trial
(PA-172) The Role of CHIP Mutations in Plasma Cell Dyscrasias: Implications for Clonal Evolution and Risk Stratification
(PA-175) Comprehensive Characterization and Pharmacological Targeting of Stem‐like Side Population Compartment in Multiple Myeloma
(PA-178) Integrating p53 Protein Expression with Mutation and Copy Number Status Enhances Risk Assessment in Myeloma
(PA-182) Minimal Residual Disease Kinetics in Patients with Multiple Myeloma Receiving First Line Treatment and the Association with their Progression-Free Survival; A Retrospective Study of 323 patients
(PA-186) Deciphering Genomic Correlates of Differential Treatment Response Kinetics in Multiple Myeloma
(PA-189) Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EASYM) in patients with Newly Diagnosed Multiple Myeloma
(PA-192) Refining MRD Surveillance in Multiple Myeloma: Predictive Insights from Ultrasensitive Bone Marrow Analysis
(PA-195) Profiling Minimal Residual Disease with Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Patients Receiving BCMA- or GPRC5D-Targeted Agents
(PA-198) Identification of a CAR–Derived Clone by NGS-based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma
(PA-202) Dynamic Changes in Cytogenetic Abnormalities Detected by Serial FISH Predict MRD Status and Outcomes in Multiple Myeloma
(PA-208) Multi-Omic Profiling of NK Cell Dysfunction and Tumor Immune Escape in Multiple Myeloma Evolution
(PA-211) Cyclin D1 Beyond the Cell Cycle: A New Role in t(11;14) MM
(PA-214) Expression Profile–Based Dissemination Score for Myeloma Prognostication
(PA-217) Potential Roles of YBX1-MIF Axis in Promoting Bone Marrow Inflammation and Multiple Myeloma Progression
(PA-220) Integrated Multi-omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution
(PA-221) Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma
(PA-224) Referral of Select Multiple Myeloma Patients for Genetic Evaluation Leads to 5-Fold Increase in Pathogenic Germline Variant Detection
(PA-225) Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
(PA-229) Machine Learning–Based Unsupervised Molecular Subtyping of Malignant Plasma Single-Cell RNA Data Reveals Tumor-Immune Features Linked to Poor Outcomes in Multiple Myeloma
(PA-232) Investigating Ribosome-targeting Therapies for the Treatment of Relapsed/refractory Multiple Myeloma
(PA-235) Imbalance of Glycine Metabolism Contributes to Osteolysis in Multiple Myeloma
(PA-238) Immunomodulatory Drugs (IMiDs) induce the expression of long non-coding RNAs NEAT1 and NEAT1_2 in myeloma cells
(PA-241) Clinical Impact of Cytogenetic Abnormalities and Detection Discordance between Conventional Karyotyping and FISH in Multiple Myeloma
(PA-244) Targeting PIM-2 and PARP1 Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells Through NKG2D Binding
(PA-247) Multiple Myeloma Patients with Admixture-defined African Ancestry Have Equal Clinical Outcomes to Those with European Ancestry When Receiving Highly Effective Therapies
(PA-249) Contribution of ARID1A Mutations in the Development of Extramedullary Plasmacytoma
(PA-253) Immunosuppressive Bone Marrow Microenvironment Promotes Multiple Myeloma Proliferation in Adult Mice with Induced Osteoblast and Osteocyte Deficiency
(PA-258) Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics.
(PA-261) Comparison of NGS-Based PlasmaSeq and FISH for Routine Genomic Testing in Multiple Myeloma
(PA-264) Treatment of Plasma Cell Disorders Post Solid Organ Transplant – A Positive Single Center Experience using Immunomodulatory Drugs
(PA-267) Tumor-immune Microenvironment Interaction Drives the Co-evolution of Multiple Myeloma and Immune Cells in a Novel Mouse Model Engineered with Human Immune System
(PA-271) Study on Loss of Sex Chromosomes in Peripheral Blood Cells of Patients with Multiple Myeloma: A Cross-sectional Analysis in Indian Setup
(PA-277) Crosstalk Between m6A and H3K27ac via the YTHDC1-EP300 Feedback Loop Promotes Myelomagenesis
(PA-280) The m5c-binding Protein YB-1 Modulates Proteasome Inhibitors Resistance in Multiple Myeloma via Epigenetic Modification
(PA-287) A New Pikfyve Inhibitor Shows Subnanomolar Potency in Multiple Myeloma
(PA-288) Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1
(PA-291) Comparative Analysis of Motixafortide versus Plerixafor for Stem Cell Mobilization and Collection in Multiple Myeloma: A Single Center Real-world Experience
(PA-294) Safety Profile and Toxicity Comparison of Bispecific Antibodies in Relapse Refractory Multiple Myeloma: A Systematic Review of Clinical Trials
(PA-295) Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
(PA-298) Uncovering Shared Cancer-restricted Cryptic Antigens as T Cell Targets in Multiple Myeloma Patients Treated with Dendritic Cell/Myeloma Fusion Vaccine
(PA-301) Enhancing Immunotherapy through Metabolic Modulation in Humanized Multiple Myeloma Mice
(PA-305) Computer-assisted AI to Detect Myeloma Cells
(PA-309) SETD7 Is a Novel Therapeutic Target for Multiple Myeloma Carrying t(11;14)
(PA-312) B7-H3 Is Associated with Worse Outcomes in Newly Diagnosed Myeloma and Can Be Targeted with a Tri-specific Killer Engager
(PA-316) Ex vivo Evaluation of BCL-2 Family Member Dependencies in Multiple Myeloma: Synergistic Combinations and Biomarkers of Sensitivity and Resistance
(PA-320) Unc-51 Like Kinase 3 (ULK3) is Essential for Autophagy and Cell Survival in Multiple Myeloma
(PA-326) Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation in Multiple Myeloma
(PA-328) Inhibition of DNA Damage Response Factor DNA-PKcs-mediated H2AX Phosphorylation Enhances Selinexor-induced Anti-multiple Myeloma Effects
(PA-329) A Multi-step Virtual Screening Framework Identifies Novel GPRC5D Inhibitors for Multiple Myeloma Therapy
(PA-335) Assessment of Knowledge and Diagnostic Competence on MGUS Among Primary Care Physicians in Southern Brazil
(PA-338) Clinical Characteristics and Long Term Outcomes of Poems Syndrome from a Tertiary Care Cancer Center
(PA-341) Primary Results from A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
(PA-344) Treatment Paradigms and Outcomes for Light Chain Amyloidosis Associated with Waldenstrom's Macroglobulinemia
(PA-348) Diagnostic Patterns and Outcomes of Amyloidosis Screening in a Monoclonal Gammopathy Clinic: A Single Center Study
(PA-351) Cutaneous Manifestation of Monoclonal Gammopathy : Clinical Challenges and Management
(PA-354) Profound Decrease of dFLC After One Cycle Predicts Superior Outcome in Patients with AL Amyloidosis Treated with Daratumumab and Bortezomib-Based Regimens
(PA-355) Real-world Impact of Anti-CD38 Monoclonal Antibodies and Hematopoietic Stem Cell Transplant in Primary Plasma Cell Leukemia (2021 IMWG Criteria): A Single-center Analysis
(PA-359) Diffuse Bone Marrow Activity as Prognostic Biomarker in Patients with Smouldering Multiple Myeloma
(PA-362) Investigating the Role of the BAFF-APRIL System in Promoting Progression of Smouldering Myeloma (SMM)
(PA-365) Clinical Profile, Treatment Patterns, Outcomes and Predictors of Survival in Al Amyloidosis: A Retrospective Study from a Tertiary Cancer Center
(PA-367) Mortality and Inpatient Hospitalization Rates Amongst Light-Chain Amyloidosis (AL) Patients During the Daratumumab Era: Results from an Analysis of US Medicare Fee-for-Service (FFS) Beneficiaries
(PA-370) Efficacy and Safety of Daratumumab-Based Regimens in Light Chain Amyloidosis: A Retrospective Single-Center Study
(PA-373) Subcutaneous Daratumumab + Bortezomib, Cyclophosphamide, and Dexamethasone in Asian Patients with Newly Diagnosed Light-chain (AL) Amyloidosis: Subgroup Final Analysis of the Phase 3 ANDROMEDA Study
(PA-379) Health-related Quality of Life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone
(PA-382) Frailty and Social Deprivation Affect Real-world Outcomes in Multiple Myeloma (MM) – an England-wide Cohort Study from the UNCOVER Study Group and UKMRA Frailty Group
(PA-383) HSPA9 Contributes to Tumor Progression and Ferroptosis Resistance by Enhancing USP14-Driven xCT Deubiquitination in Multiple Myeloma
(PA-386) Daratumumab, Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance in Transplant-eligible Multiple Myeloma Patients: Overall Survival Comparison with the CASSIOPEIA Trial
(PA-389) Uncovering Hidden Prognostic Patterns in Multiple Myeloma: A Novel Unsupervised Deep-learning Method for Risk Factor Discovery
(PA-392) Temporal Trends in Multiple Myeloma Mortality in Ecuador, 2010 – 2022: A Nationwide Joinpoint Analysis
(PA-395) Race, Lenalidomide Dosing, and Survival in Newly Diagnosed Transplantation-Ineligible Multiple Myeloma Patients
(PA-398) Overview of First-Line Treatment of Multiple Myeloma Patients from Two Hematology Centers in Slovakia – Data from the RMG Registry
(PA-402) Incidence and Timing of Infections in Patients with Newly Diagnosed Myeloma Treated with Contemporary Regimens
(PA-404) A Randomized Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (KRd) with Elotuzumab-KRd in Transplant-eligible Patients with Newly Diagnosed Myeloma: Initial Results for 3-year PFS and OS
(PA-407) Prognostic Subgroups in Hyperdiploid Myeloma and the Role of Modern Treatments
(PA-411) Daratumumab as Post-ASCT Maintenance in Multiple Myeloma Patients with Lenalidomide Intolerance/toxicity: Results from a Single Center over the Last 5 Years
(PA-414) Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
(PA-415) Definition of Transplant Ineligibility in Newly Diagnosed Multiple Myeloma: A Systematic Review
(PA-419) Retrospective Analysis of Newly Diagnosed Multiple Myeloma Patients with Partial or Worse Response to First-line Induction Therapy
(PA-422) Frontline Bortezomib-Based Therapy and Autologous Hematopoietic Stem Cell Transplantation in Latin American Multiple Myeloma Patients: Insights from a Real-World Multinational Cohort
(PA-425) Enhancing GAH Score to Optimize Tolerance to Quadruplet Therapies in Multiple Myeloma: A Subanalysis of the GEM2017FIT Trial
(PA-428) Clinico-hematological and Cytogenetic Profile of Multiple Myeloma Patients in a North Indian Tertiary Care Hospital
(PA-431) Global Research Trends and Inequities in Clinical Trials in Multiple Myeloma: A Focus On South and Southeast Asia
(PA-434) Renal Histopathologic Spectrum and Factors Associated with Reversibility of Renal Injury in Newly Diagnosed Patients of Multiple Myeloma
(PA-438) Pan-Pacific Multiple Myeloma (MM) Working Group Guidelines and Recommendations for CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed MM
(PA-442) Outcomes and Maintenance Strategies for Transplant-Eligible Newly Diagnosed Multiple Myeloma Among Patients Age 40 and Younger
(PA-445) DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
(PA-449) Survival of IgA Multiple Myeloma at the National Cancer Institute of Peru
(PA-453) Efficacy of Daratumumab-bortezomib-lenalidomide-dexamethasone (DVRd) vs Daratumumab-lenalidomide-dexamethasone (DRd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
(PA-456) Treatment Outcomes in Isolated Gain1q Multiple Myeloma Patients
(PA-459) Efficacy and Safety of Ixazomib-Based Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: A Retrospective Analysis
(PA-465) Factors Influencing CAR T-Cell vs. Bispecific Antibody Preferences in Relapsed/Refractory Multiple Myeloma
(PA-468) Nanobody-based Multifunctional Killer Engagers for Next-Gen BCMA-Directed Myeloma Therapy
(PA-471) CYP3A4 Modulators Do Not Affect the Pharmacokinetics of Selinexor
(PA-472) PomCyDex in Relapsed/Refractory Multiple Myeloma: Impact of Prior Refractoriness in a Real-World Setting
(PA-473) Carfilzomib Use and Therapeutic Sequences in Patients with Relapsed/refractory Multiple Myeloma in France: An Analysis from a Large-scale Epidemiology of Multiple Myeloma (EmmY) Cohort
(PA-476) What Matters to Patients on Bispecific Antibodies for Relapsed/Refractory Myeloma: Priorities, Symptom Burden, and Delivery Preferences
(PA-478) Selinexor in Combination with Pomalidomide and Dexamethasone for Patients with Relapsed and/or Refractory Multiple Myeloma (SCOPE Trial)
(PA-481) Socioeconomic Factors Affecting Health Equity in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
(PA-484) Differences in Treatment Goals and Expectations Among Patients with Relapsed/refractory Multiple Myeloma Treated in Academic vs Community Settings
(PA-487) Real-world Evidence of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/refractory Multiple Myeloma Patients: Efficacy and Safety from a Single-center Experience
(PA-492) Association Between Progression-Free Survival and Overall Survival Outcomes in Patients with Multiple Myeloma Previously Treated with Lenalidomide and an ANTI-CD38 Regimen: A Real-World Perspective
(PA-496) Time Toxicity Associated with Selinexor-pomalidomide-dexamethasone versus Other Treatments for Relapsed/refractory Multiple Myeloma
(PA-499) A Network Meta-Analysis of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Alternative Regimens in 2L+ Relapsed/Refractory Multiple Myeloma: Updated Efficacy Outcomes of DREAMM-7
(PA-502) Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
(PA-506) Isatuximab Subcutaneous via an On-body Injector Plus Pomalidomide-dexamethasone in Relapsed/refractory Multiple Myeloma: Subgroup Analysis by Prior Lines of Therapy from the Phase 3 IRAKLIA Trial
(PA-509) Real-world Use and Effectiveness of Venetoclax in Combination with Carfilzomib Plus Dexamethasone in t(11;14)-positive Relapsed/refractory Multiple Myeloma: A Single-center Retrospective Study
(PA-512) Real-world Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Three Belgian Academic Hospitals
(PA-515) Real-world Characteristics and Outcomes of Patients with Relapsed or Refractory Multiple Myeloma Treated with Talquetamab: Early Results from eMMpower Consortium
(PA-520) Efficacy and Safety of Low-frequency Daratumumab in Systemic Light-chain Amyloidosis
(PA-521) Evolution of Age and Causes of Death in Patients with Multiple Myeloma in the Era of Novel Agents
(PA-522) Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma
(PA-526) Patterns of Use of Free Light Chain Testing in Patients with Multiple Myeloma in Colombia
(PA-527) Population Pharmacokinetic Model-Based Melphalan Dosing with Siltuximab Interleukin-6 Blockade in Older Multiple Myeloma Patients Undergoing AHCT: Phase II Run-In Results
(PA-532) Targeting JAM-A to Prevent Multiple Myeloma Progression: Novel Peptide Inhibitors Block Proliferation and Offer a New Therapeutic Strategy for High-Risk Disease
